Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
暂无分享,去创建一个
H. May | B. Coll | J. Muhlestein | Yuhui Ma | J. López | J. Nelson | J. A. G. López | J. A. López
[1] P. Barter,et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial , 2018, Circulation.
[2] J. Nelson,et al. ApoA1 Remnant Ratio in Very High Risk Patients with LDL-c 55 Years of Age , 2018 .
[3] S. Martin,et al. Effect of Evolocumab on Lipoprotein Particles. , 2018, The American journal of cardiology.
[4] Lawrence A Leiter,et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.
[5] P. Ridker,et al. Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins , 2017, Journal of the American Heart Association.
[6] Marc P. Bonaca,et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.
[7] N. Wong. Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial). , 2017, The American journal of cardiology.
[8] E. Stroes,et al. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. , 2017, Atherosclerosis. Supplements.
[9] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[10] B. Horne,et al. The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study , 2016, European journal of preventive cardiology.
[11] R. D'Agostino,et al. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies , 2016, Journal of the American Heart Association.
[12] Jennifer G. Robinson,et al. CLINICAL EQUIVALENCE OF EVOLOCUMAB AMONG PATIENT SUBGROUPS IN PROFICIO: A POOLED ANALYSIS OF 3146 PATIENTS FROM PHASE 3 STUDIES , 2015 .
[13] M. Emery,et al. Evolocumab (AMG 145) for primary hypercholesterolemia , 2015, Expert review of cardiovascular therapy.
[14] Lesley Burgess,et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[15] Z. Awan,et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. , 2014, Clinical chemistry.
[16] P. Toth,et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. , 2014, Atherosclerosis.
[17] H. Bays,et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.
[18] Jennifer G. Robinson,et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. , 2014, JAMA.
[19] C. Ballantyne,et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. , 2014, The New England journal of medicine.
[20] B. Nordestgaard,et al. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. , 2014, Pharmacology & therapeutics.
[21] A. Gotto,et al. Residual macrovascular risk in 2013: what have we learned? , 2014, Cardiovascular Diabetology.
[22] B. Nordestgaard,et al. Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.
[23] A. Prat,et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1) , 2013, PloS one.
[24] B. Horne,et al. A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL]) , 2013, Lipids in Health and Disease.
[25] B. Nordestgaard,et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.
[26] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[27] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[28] Yan Wang,et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates , 2009, Proceedings of the National Academy of Sciences.
[29] A. Prat,et al. The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2* , 2008, Journal of Biological Chemistry.
[30] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .
[31] S. Devaraj,et al. Remnant lipoproteins: measurement and clinical significance. , 2002, Clinical chemistry.
[32] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.
[33] D. A. Chappell,et al. Receptor-mediated mechanisms of lipoprotein remnant catabolism. , 1998, Progress in lipid research.
[34] A. Cooper. Hepatic uptake of chylomicron remnants. , 1997, Journal of lipid research.
[35] Sadao Takahashi,et al. Enhancement of the Binding of Triglyceride-rich Lipoproteins to the Very Low Density Lipoprotein Receptor by Apolipoprotein E and Lipoprotein Lipase (*) , 1995, The Journal of Biological Chemistry.
[36] C. E. Becker. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.
[37] The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.